{"title":"To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist?","authors":"Amol Akhade, Aju Mathew","doi":"10.1055/s-0042-1746411","DOIUrl":null,"url":null,"abstract":"Survival of early-stage hormone receptor (HR)-positive and human epidermal receptor 2 (HER2)-negative breast cancer has signi fi cantly improved over the last three decades. Adjuvant chemotherapy plays an important role in this advance-ment. 1 However, we have also learnt that the bene fi t of chemotherapy is not for all patients. 2 Some patients may be overtreatedwithchemotherapyresultinginavoidabletoxicity. Some may be undertreated resulting in lackofcure. Therefore, a predictive biomarker is of great demand. Such a biomarker will helptheoncologist in deciding treatmentcourse, whether to give or not to give adjuvant chemotherapy. fi eld fi nessed","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"11 1","pages":"1-2"},"PeriodicalIF":0.6000,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/f1/10-1055-s-0042-1746411.PMC9273325.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1746411","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
Survival of early-stage hormone receptor (HR)-positive and human epidermal receptor 2 (HER2)-negative breast cancer has signi fi cantly improved over the last three decades. Adjuvant chemotherapy plays an important role in this advance-ment. 1 However, we have also learnt that the bene fi t of chemotherapy is not for all patients. 2 Some patients may be overtreatedwithchemotherapyresultinginavoidabletoxicity. Some may be undertreated resulting in lackofcure. Therefore, a predictive biomarker is of great demand. Such a biomarker will helptheoncologist in deciding treatmentcourse, whether to give or not to give adjuvant chemotherapy. fi eld fi nessed